tested if alterations in dysbindin mRNA were found in the hippocampus of patients with schizophrenia by using in situ hybridization. We found signifi cantly reduced dysbindin mRNA in the dentate gyrus, CA4 and CA3, but not CA1, subregions of the hippocampus of patients with schizophrenia as compared with normal controls. Additionally, we found that dysbindin mRNA levels strongly and positively correlated with synaptophysin and spinophilin mRNA levels, which are known to be reduced in patients with schizophrenia. Our results suggest that reductions in dysbindin protein previously found in the hippocampus of patients with schizophrenia may be because of decreased dysbindin mRNA. The signifi cant reduction of dysbindin mRNA found in the hippocampus confi rms and extends our initial fi ndings that dysbindin mRNA is signifi cantly reduced in the frontal cortex and tends to be decreased in the midbrain of patients with schizophrenia (Weickert et al. 2004). Taken together, our results suggest that dysbindin mRNA reduction is not anatomically restricted, but may be anatomically specifi c, in the brains of patients with schizophrenia. Furthermore, subfi eld-specifi c reductions in dysbindin mRNA may lead to subfi eld-specifi c synaptic pathology in the hippocampus of patients with schizophrenic.
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